Journal of Antimicrobial Chemotherapy

Papers
(The median citation count of Journal of Antimicrobial Chemotherapy is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-09-01 to 2024-09-01.)
ArticleCitations
Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder342
The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community123
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study108
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis96
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey93
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study86
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London75
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries69
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials60
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection58
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital57
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-1957
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study55
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections51
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients51
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages51
Oxazolidinones: mechanisms of resistance and mobile genetic elements involved50
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge48
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial44
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections40
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid40
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 201839
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates38
Molecular mechanisms driving thein vivodevelopment of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDRPseudomonas aeruginosainfectio37
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre37
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia37
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–201737
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 201937
Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics36
In vitrosusceptibility ofMycobacterium abscessuscomplex and feasibility of standardizing treatment regimens36
Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile36
Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?35
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria34
Impact of an antimicrobial stewardship programme on reducing broad-spectrum antibiotic use and its effect on carbapenem-resistantAcinetobacter baumannii(CRAb) in hospitals in Jordan34
IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bactera34
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications33
Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis33
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)33
AMR-Intervene: a social–ecological framework to capture the diversity of actions to tackle antimicrobial resistance from a One Health perspective33
Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review33
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases32
Transferable Acinetobacter baumannii plasmid pDETAB2 encodes OXA-58 and NDM-1 and represents a new class of antibiotic resistance plasmids32
Large diversity of linezolid-resistant isolates discovered in food-producing animals through linezolid selective monitoring in Belgium in 201932
Ganciclovir therapeutic drug monitoring in transplant recipients31
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing31
Antibiotics and healthcare facility-associatedClostridioides difficileinfection: systematic review and meta-analysis 2020 update31
Do high MICs predict the outcome in invasive fusariosis?31
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society 31
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa31
In vitroactivity of the novel antifungal olorofim against dermatophytes and opportunistic moulds includingPenicilliumandTalaromycesspecies30
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)30
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial30
Molecular epidemiology of carbapenemase-producingEscherichia colifrom duck farms in south-east coastal China30
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-1930
ESBL-producing strains isolated from imported cases of enteric fever in England and Wales reveal multiple chromosomal integrations of blaCTX-M-15 in XDR Salmonella Typhi29
Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring28
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis28
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial28
One Health compartmental analysis of ESBL-producing Escherichia coli on Reunion Island reveals partitioning between humans and livestock28
Molecular dynamics simulations informed by membrane lipidomics reveal the structure–interaction relationship of polymyxins with the lipid A-based outer membrane of Acinetobacter baumannii28
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial28
Delamanid or pretomanid? A Solomonic judgement!28
Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections27
High percentage of the ceftriaxone-resistantNeisseria gonorrhoeaeFC428 clone among isolates from a single hospital in Hangzhou, China27
Class D β-lactamases27
Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates27
Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020–2127
Prevalence and genomic analysis of ESBL-producingEscherichia coliin retail raw meats in Singapore27
Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 201927
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting26
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis26
Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases26
Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales26
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa26
A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections26
Invasive candidiasis: current clinical challenges and unmet needs in adult populations26
Evolution of β-lactamase-mediated cefiderocol resistance26
In vitroactivity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli fro25
Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015–19)25
In vitroactivity of rifabutin against 293 contemporary carbapenem-resistantAcinetobacter baumanniiclinical isolates and characterization of rifabutin mode of action and resistance mechan25
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates25
Detection ofmcr-9-harbouring ESBL-producingSalmonellaNewport isolated from an outbreak in a large-animal teaching hospital in the USA25
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK24
Characterization of Klebsiella pneumoniae complex isolates from pigs and humans in farms in Thailand: population genomic structure, antibiotic resistance and virulence genes24
Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic24
Management ofClostridioides difficileinfection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines24
Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children24
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–24
Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening24
Genomic analysis of 600 vancomycin-resistant Enterococcus faecium reveals a high prevalence of ST80 and spread of similar vanA regions via IS1216E and plasmid transfer in diverse 24
Defining the scope of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet): a bottom-up and One Health approach24
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study24
Novel tigecycline resistance gene cluster tnfxB3-tmexCD3-toprJ1b in Proteus spp. and Pseudomonas aeruginosa, co-existing with tet(X6) on an SXT/R391 integrative and 24
Emergence of a multidrug resistance efflux pump with carbapenem resistance gene blaVIM-2 in a Pseudomonas putida megaplasmid of migratory bird origin24
IS26cannot move alone24
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones24
Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world23
Carbapenemase-producing Enterobacteriaceae in transplant patients23
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis23
Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study23
A review of remdesivir for COVID-19 in pregnancy and lactation23
Neisseria gonorrhoeaeSequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antim23
Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey23
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study23
Revealing antibiotic cross-resistance patterns in hospitalized patients through Bayesian network modelling23
Epidemiology, clinical aspects, outcomes and prognostic factors associated with Trichosporon fungaemia: results of an international multicentre study carried out at 23 medical centres22
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients22
Characterization and outcome of invasive infections due toPaecilomyces variotii: analysis of patients from the FungiScope® registry and literature reports22
IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis22
Identification of thresholds in relationships between specific antibiotic use and carbapenem-resistantAcinetobacter baumannii(CRAb) incidence rates in hospitalized patients in Jordan21
Characterization of novel ISAba1-bounded tet(X15)-bearing composite transposon Tn6866 in Acinetobacter variabilis21
Point prevalence survey of antibiotic use in hospitals in Latin American countries21
Invasive infections withPurpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature21
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments21
Mechanisms of antibiotic resistance of Clostridioides difficile21
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-221
Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis21
Occurrence of a plasmid co-carrying cfr(D) and poxtA2 linezolid resistance genes in Enterococcus faecalis and Enterococcus casseliflavus from porcine manure, Italy21
Establishing essential metrics for antifungal stewardship in hospitals: the results of an international Delphi survey21
Comparative phylogenomics of ESBL-, AmpC- and carbapenemase-producing Klebsiella pneumoniae originating from companion animals and humans21
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2in vitroandin vivo20
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation20
EUCAST rapid antimicrobial susceptibility testing (RAST): analytical performance and impact on patient management20
Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory20
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial20
Novel SCCmec type XV (7A) and two pseudo-SCCmec variants in foodborne MRSA in China20
Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time19
Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study19
Antifungal activity of nikkomycin Z against Candida auris19
When to change treatment of acute invasive aspergillosis: an expert viewpoint19
Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 202219
Emergence of a Neisseria gonorrhoeae clone with reduced cephalosporin susceptibility between 2014 and 2019 in Amsterdam, The Netherlands, revealed by genomic population analysis19
Spread of ESC-, carbapenem- and colistin-resistant Escherichia coli clones and plasmids within and between food workers in Lebanon19
Characterization of carbapenemase-producingSerratia marcescensand whole-genome sequencing for plasmid typing in a hospital in Madrid, Spain (2016–18)19
Treating COVID-19: are we missing out the window of opportunity?19
A nationwide genomic study of clinical Klebsiella pneumoniae in Norway 2001–15: introduction and spread of ESBLs facilitated by clonal groups CG15 and CG30719
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital19
Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae19
Role of new antibiotics for KPC-producingKlebsiella pneumoniae19
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?19
Phenotypic and genomic analysis reveals Riemerella anatipestifer as the potential reservoir of tet(X) variants18
Two high-risk clones of carbapenemase-producing Klebsiella pneumoniae that cause infections in pets and are present in the environment of a veterinary referral hospital18
Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and charact18
Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model18
Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection ofEscherichia coli and Klebsiella pneumoniaeharbouring serine- and New Delhi metallo-β-lactamases18
Comparative genomics of ESBL-producingEscherichia coli(ESBL-Ec) reveals a similar distribution of the 10 most prevalent ESBL-Ec clones and ESBL genes among human community faecal and extra-inte18
Respiratory antibacterial prescribing in primary care and the COVID-19 pandemic in England, winter season 2020–2118
Genetic features of the poxtA linezolid resistance gene in human enterococci from France18
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods18
Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: an observational, cross-sectional study18
Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study17
Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey17
The impact of anti-mould prophylaxis onAspergillusPCR blood testing for the diagnosis of invasive aspergillosis17
Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and meta-analysis17
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and17
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections17
Consumption of quinolones in the community, European Union/European Economic Area, 1997–201717
Acquisition of a genomic resistance island (AbGRI5) from global clone 2 through homologous recombination in a clinical Acinetobacter baumannii isolate17
Identification of 16S rRNA mutations in Mycoplasma genitalium potentially associated with tetracycline resistance in vivo but not selected in vitro in M. genitalium and 17
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases17
The bla and mec families of β-lactam resistance genes in the genera Macrococcus, Mammaliicoccus and Staphylococcus: an in-depth analysis with emphasis on Macrococ17
Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients17
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-1917
In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii17
Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization inEscherichia coli17
Azithromycin in patients with COVID-19: a systematic review and meta-analysis16
Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae16
Detection in livestock of the human pandemic Escherichia coli ST131 fimH30(R) clone carrying blaCTX-M-2716
PrEP monitoring and HIV incidence after PrEP initiation in France: 2016–18 nationwide cohort study16
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales16
Thiocillin and micrococcin exploit the ferrioxamine receptor of Pseudomonas aeruginosa for uptake16
Cefepime-induced neurotoxicity: systematic review16
Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs16
Legionellaantibiotic susceptibility testing: is it time for international standardization and evidence-based guidance?16
Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates16
The impact of digital interventions on antimicrobial stewardship in hospitals: a qualitative synthesis of systematic reviews16
Resistance/fitness trade-off is a barrier to the evolution of MarR inactivation mutants in Escherichia coli16
Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance16
Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis16
An outbreak of multiply antibiotic-resistant ST49:ST128:KL11:OCL8Acinetobacter baumanniiisolates at a Sydney hospital16
In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae16
Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis16
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation16
Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria16
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones16
In vitroevolution of cefepime/zidebactam (WCK 5222) resistance inPseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact onin vivoefficacy15
Emergence of VIM-producing Enterobacter cloacae complex in France between 2015 and 201815
Clinical characteristics and management of olecranon and prepatellar septic bursitis in a multicentre study15
An updated phylogeny of the metallo-β-lactamases15
Clonal relationship of tet(X4)-positive Escherichia coli ST761 isolates between animals and humans15
Dalbavancin in Gram-positive periprosthetic joint infections15
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control15
Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997–201715
Antibiotic use during pregnancy and the risk of preterm birth: a population-based Swedish cohort study15
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers15
AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics15
Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region15
Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015–1815
Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules15
Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis15
VraCP regulates cell wall metabolism and antibiotic resistance in vancomycin-intermediateStaphylococcus aureusstrain Mu5015
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis15
Loss of outer membrane protein A (OmpA) impairs the survival of Salmonella Typhimurium by inducing membrane damage in the presence of ceftazidime and meropenem15
Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) β-lactamase enzymes inAcinetobacter baumannii15
Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study15
Persistence of a multidrug-resistant worldwide-disseminated methicillin-resistant Staphylococcus epidermidis clone harbouring the cfr linezolid resistance gene in a French hospital with 15
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation15
What are the most effective community-based antimicrobial stewardship interventions in low- and middle-income countries? A narrative review15
Salmonella enterica serovar Typhi H58 clone has been endemic in Zimbabwe from 2012 to 201915
Antimicrobial peptide WAM-1: a promising antibacterial and anti-inflammatory drug against carbapenem-resistant Klebsiella pneumoniae14
Identification of a novel tetracycline resistance gene, tet(63), located on a multiresistance plasmid from Staphylococcus aureus14
Characterization of the novel optrA-carrying pseudo-compound transposon Tn7363 and an Inc18 plasmid carrying cfr(D) in Vagococcus lutrae14
Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-1914
Redefining therapeutic success in HIV patients: an expert view14
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales14
Linezolid-resistant Enterococcus gallinarum isolate of swine origin carrying cfr, optrA and poxtA genes14
Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision14
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study14
Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses14
Impact of pre-existing drug resistance on risk of virological failure in South Africa14
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings14
Liposomal amphotericin B—the past14
SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study14
Pet husbandry as a risk factor for colonization or infection with MDR organisms: a systematic meta-analysis14
A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa14
A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva14
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)14
The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems14
Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance14
Liposomal amphotericin B—the present14
The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids14
Detection of the transferable tigecycline resistance gene tet(X4) in Escherichia coli from pigs in the United Kingdom14
Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim14
Dissemination of Klebsiella pneumoniae ST147 NDM-1 in Poland, 2015–1914
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial14
Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study14
In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile14
Evaluation of a diagnostic algorithm for rapid identification of Gram-negative species and detection of extended-spectrum β-lactamase and carbapenemase directly from blood cultures14
Inhibition of d-alanylation of teichoic acids overcomes resistance of methicillin-resistant Staphylococcus aureus14
Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam inPseudomonas aeruginosaisolates recovered from ICU patients in Spain and Portugal depicted by WGS14
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)14
Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections14
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV14
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales13
Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain13
Characterization of the novel plasmid-encoded MBL gene blaAFM-1, integrated into a blaIMP-45-bearing transposon Tn6485e in a carbapenem-resistant Pseudomonas aeruginosa cli13
Clinical exposure–response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model13
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae13
Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay13
A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004–20 in Spain13
0.51745986938477